Tri-Institutional Tuberculosis Research Advancement Center (TRAC)

三机构结核病研究促进中心 (TRAC)

• 批准号: 10430737
• 负责人: Daniel W Fitzgerald
• 金额: $ 103.44万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10430737
• 关键词: Address; Animal Model; Area; Award; Basic Science; Biochemistry; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communication Programs; Development; Discipline; Educational workshop; Environment; Faculty; Fostering; Funding; Genetic; Goals; Haiti; Human Genetics; Immunology; Institution; Interdisciplinary Study; International; Leadership; Libraries; Maps; Medicine; Memorial Sloan-Kettering Cancer Center; Mentorship; Microbiology; Minority Women; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; New York City; Postdoctoral Fellow; Prevention; Program Evaluation; Research; Research Personnel; Research Priority; Research Project Grants; Research Training; Resources; Sampling; Science; Scientist; Site; Strategic Planning; Tanzania; Technical Expertise; Technology; Translational Research; Travel; Tuberculosis; Underrepresented Minority; United States National Institutes of Health; Universities; Woman; biobank; career; clinical research site; drug discovery; experience; implementation science; improved; innovation; member; mortality; multidisciplinary; mycobacterial; organizational structure; programs; recruit; symposium; tuberculosis diagnostics

Overall Abstract: We propose a Tri-Institutional Tuberculosis (TB) Research Advancement Center (TRAC) at Weill Cornell Medicine, Memorial Sloan-Kettering Cancer Center and Rockefeller University. The three institutions are adjacent to each other on a Tri-Institutional (Tri-I) campus in New York City. The purpose of the proposed Tri-I TRAC is to pool the expertise and resources of an outstanding team of 20 senior TB investigators at the three institutions to expand the number of investigators in the field of TB research and to promote innovative multidisciplinary TB research. The senior investigators have diverse expertise spanning biochemistry, basic microbiology, mycobacterial genetics, human genetics and immunology, drug discovery, international clinical trials, and implementation science. A major focus will be supporting New Investigators (NIs), who we define as senior post-doctoral fellows or junior faculty members who seek an academic career and have not yet received an R01. We also will recruit New to TB (N2TB) Investigators, who are R01 experienced investigators in other scientific disciplines who bring their expertise to study TB. The TRAC will have four Cores. The Administrative Core will provide leadership, financial oversight, communication, and program evaluation. A Developmental Core will fund 6 Developmental Project Awards annually of $50,000 each to support NIs and N2TB investigators. Institutional support from Weill Cornell Medicine will fund two of these awards each year which will be designated for under-represented minorities and women scientists. The Clinical Core will build upon long-standing collaborations primarily in Haiti and also in Tanzania. The Basic and Clinical Science Cores will provide NI and N2TB recipients of Developmental Project Awards mentorship, technical expertise, and scientific resources unique to TB research including access to TB animal models, genetically modified mycobacterial libraries, and biobanked clinical samples. The Basic and Clinical Science Cores will also facilitate sharing of technology and resources between senior TB investigators in order to initiate new lines of collaborative translational TB research. Other activities including an annual symposium, a technology workshop, and travel to international TB clinical sites will bolster the pipeline of new TB investigators and generate an environment conducive to multidisciplinary collaboration. There will be no overlap with other NIH research grants, centers, or institutional cores. The TRAC will leverage these existing resources and synergistically expand the number of TB investigators and foster new innovative lines of collaboration. Our goal over 5 years is to have 25 NIs successfully compete for a TB related NIH R01 and transition to independence and to attract at least 5 N2TB investigators to TB science. Half will be women and at least 20% underrepresented minorities. We will also initiate new lines of collaborative translational research to address the five NIAID priorities in TB science with the ultimate goal of improving TB diagnostics, prevention, and treatment and ending morbidity and mortality from TB world-wide.

总体摘要：我们提出了一个三机构结核病（TB）研究促进中心 （TRAC）在威尔康奈尔医学，纪念斯隆-凯特琳癌症中心和洛克菲勒大学。的 三个机构在纽约市的三机构（Tri-I）校园中彼此相邻。目的 拟议的Tri-I TRAC的一个主要目标是汇集一个由20名资深结核病专家组成的优秀团队的专门知识和资源 三个机构的研究人员，以扩大结核病研究领域的研究人员人数， 促进创新的多学科结核病研究。高级调查员拥有各种专业知识 涵盖生物化学、基础微生物学、分枝杆菌遗传学、人类遗传学和免疫学、药物 发现、国际临床试验和实施科学。一个主要的重点将是支持新的 研究人员（NI），我们将其定义为高级博士后研究员或初级教员，他们寻求 学术生涯，尚未收到R 01。我们还将招募新的结核病（N2 TB）研究者， 他们是R 01在其他科学学科中经验丰富的研究人员，他们将自己的专业知识用于研究结核病。的 TRAC将有四个核心。行政核心将提供领导，财务监督， 沟通和方案评估。一个发展核心将资助6个发展项目奖 每年为NIs和N2 TB研究人员提供5万美元的支持。Weill Cornell的机构支持 医学部每年将为其中两个奖项提供资金，这些奖项将指定用于代表性不足的少数民族 女科学家。临床核心将建立在长期合作的基础上，主要是在海地， 也在坦桑尼亚。基础和临床科学核心将为NI和N2 TB接受者提供发展 项目奖励结核病研究所独有的指导、技术专长和科学资源，包括 获得结核病动物模型、转基因分枝杆菌文库和生物库临床样本。的 基础和临床科学核心也将促进高级结核病患者之间的技术和资源共享 研究人员，以启动新的合作转化结核病研究的路线。其他活动包括 一个年度研讨会，一个技术研讨会，以及前往国际结核病临床地点将加强 培养新的结核病研究人员，创造有利于多学科合作的环境。 不会与其他NIH研究赠款，中心或机构核心重叠。TRAC将利用 这些现有的资源，协同扩大结核病调查人员的数量，并促进新的创新 合作的路线。我们的目标是在5年内有25个国家机构成功地竞争结核病相关的国家卫生研究院R 01 向独立过渡，并吸引至少5名N2 TB研究人员从事结核病科学研究。一半将 妇女和至少20%代表不足的少数民族。我们还将启动新的合作渠道， 转化研究，以解决结核病科学中的五个NIAID优先事项，最终目标是改善结核病 诊断、预防和治疗，并在全世界范围内消除结核病的发病率和死亡率。